Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 30, 2025 07:00 ET | Source: Skye Bioscience, Inc.

Skye Bioscience to Announce Second Quarter 2025 Financial Results and Business Update on August 7, 2025

SAN DIEGO, July 30, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on advancing new therapeutic pathways for obesity and other...
June 23, 2025 07:00 ET | Source: Skye Bioscience, Inc.

Skye Bioscience Shares Nimacimab “Anatomy of Progress” Video Series and Highlights Preclinical CB1 Antibody Data Presented at the American Diabetes Association’s 85th Scientific Sessions

SAN DIEGO, June 23, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other...
June 17, 2025 07:00 ET | Source: Skye Bioscience, Inc.

Skye Bioscience to Present Expanded Preclinical CB1 Antibody Data at the American Diabetes Association’s 85th Scientific Sessions

SAN DIEGO, June 17, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other...
May 22, 2025 07:00 ET | Source: Skye Bioscience, Inc.

Skye Bioscience to Participate in Upcoming Investment Conferences

SAN DIEGO, May 22, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other...
May 19, 2025 05:00 ET | Source: Skye Bioscience, Inc.

Skye Bioscience Establishes Partnership with Arecor Therapeutics to Develop Enhanced Formulation of Obesity Candidate Nimacimab

SAN DIEGO, May 19, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other...
May 13, 2025 16:05 ET | Source: Skye Bioscience, Inc.

Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic...
May 13, 2025 07:00 ET | Source: Skye Bioscience, Inc.

Skye Bioscience Clinical Model Demonstrating Necessity of Peripheral CB1 Inhibition for Weight Loss Presented at European Congress on Obesity

• This model demonstrates that central inhibition of CB1 is not required for weight loss • Anti-CB1 inhibiting antibody, nimacimab, showed greatest peripheral restriction compared with monlunabant...
May 08, 2025 16:01 ET | Source: Skye Bioscience, Inc.

Skye Bioscience Reports First Quarter 2025 Results and Highlights Nimacimab Differentiation in Obesity

Nimacimab in combination with tirzepatide improves weight loss effect over tirzepatide alone, and shows comparable weight loss to monlunabant and tirzepatide alone in preclinical diet-induced obesity...
May 07, 2025 07:00 ET | Source: Skye Bioscience, Inc.

Skye Bioscience to Announce 2025 First Quarter Financial Results on May 8th, 2025

SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other...
April 29, 2025 07:00 ET | Source: Skye Bioscience, Inc.

Skye Bioscience to Participate in May Investment and Medical Conferences

SAN DIEGO, April 29, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and...